




A monthly report summarizing the Life Science transactions and trends in Washington State.


Washington State Transactions by Industry

Transaction Amounts per Year



Deals by Sector

*As of 2/28/19



HIGHLIGHTS

- Seattle based immunotherapy company *Immune Design* was acquired by Merck in a \$300 million deal. ([GeekWire](#), [Pitchbook](#))
- *KenSci* raised \$22 million of Series B venture funding to continue to fuel machine learning and AI technology which aims to predict when patients will become sick to reduce healthcare costs. ([Geekwire](#))
- In an equity round, Good Therapeutics raised \$11 million dollars of funding. This early stage biotech company aims to develop drugs that sense biomarkers and act only when needed. ([Geekwire](#))

This report is prepared by Laura Sconyers, MBA, MCD. Questions or comments? Contact laura@lswinstitute.org.

**The data in this report are sourced from Pitchbook, Inc. and other publicly disclosed information. It is not independently verified by Life Science Washington Institute.



Washington Life Science Transactions January - February 2019

Date	Company	Type	Amount
01/02/19	Bardy Diagnostics	Equity	\$6,000,000
01/02/19	Weconnect Health Management	Equity	\$475,000
01/02/19	Immusoft	Equity	\$20,170,000
01/04/19	Lightspeed Microscopy	Equity	\$100,000
1/22/2019	LumiThera	Equity	\$2,000,000
1/23/2019	LEVL	Equity	Undisclosed
1/25/2019	Eloupes	Equity	\$4,200,000.00
1/25/2019	Magnolia Medical Technologies	Equity	\$20,000,000.00
1/31/2019	Sentinel Healthcare	Equity	\$2,000,000.00
2/7/2019	Kensci	Equity	\$22,000,000
2/8/2019	Good Therapeutics	Equity	\$11,190,000
2/14/2019	Blaze Bioscience	Equity	\$8,000,000
2/21/2019	Healionics	Equity	\$3,810,000
2/26/2019	CorneaGen	Equity	\$48,000,000
Total			\$147,945,000